HOME Research Insight Key Players in the High Potency Active Pharmaceutical Ingredients Market Pursue Agreements, Collaborations, Partnerships, and Alliances; Regulatory Approvals; Mergers and Acquisitions; and Expansions as their Key Growth Strategies to Hold Market Position



Key Players in the High Potency Active Pharmaceutical Ingredients Market Pursue Agreements, Collaborations, Partnerships, and Alliances; Regulatory Approvals; Mergers and Acquisitions; and Expansions as their Key Growth Strategies to Hold Market Position


Prominent players in the Active pharmaceutical ingredients market include as Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).

The High potency active pharmaceutical ingredients market is highly competitive and fragmented with many big and small players as well as contract manufacturing organizations. Pfizer, Inc., a leading player in the HPAPIs market. Pfizer’s leading position in the market can be attributed to its exhaustive product portfolio spread across its business segments including Global Innovative Pharmaceuticals (GIP); Global Established Pharmaceuticals (GEP); and Global Vaccines, Oncology. As part of its growth strategy, the company focuses on adopting both organic and inorganic growth strategies such as agreements, partnerships, collaborations, approvals, and acquisitions. In accordance with this, in June 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (U.S.), a leading biopharmaceutical company developing small molecule therapeutics. Moreover, in September 2015, Pfizer acquired Hospira (U.S.), a global leader in biosimilars. This acquisition enabled the company to broaden its products offerings.  

F. Hoffmann-La Roche Ltd. (Switzerland), is another leading player in this market. The company’s strengths lie in its and exhaustive product portfolio and strong geographic presence. The company adopts and implements organic and inorganic growth strategies such as agreements, partnerships, approvals, alliances, and collaborations. In accordance with this, in December 2014, Roche entered into an agreement to acquire Dutalys GmbH (Austria), a company that specializes in the discovery and development of fully human, bi-specific antibodies based on the proprietary DutaMab technology. In November 2015, Roche invested CHF 300 million (USD 295.81 million) for restructuring its manufacturing network for small molecules. Such initiatives help the company to maintain its market share and remain competitive in the dynamic global HPAPIs market.   

The key strategies followed by most companies in the high potency active pharmaceutical ingredients market are agreements, collaborations, partnerships, and alliances; regulatory approvals; mergers and acquisitions; and expansions. Among all growth strategies adopted by market players, agreements, collaborations, partnerships, and alliances accounted for the largest share of the overall growth strategies mapped from 2013 to 2016. Some leading players adopting these strategies include Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sanofi (France), Eli Lilly and Company (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and Merck & Co., Inc. (U.S.).

Related Reports:

High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

 

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports